Europe Alzheimer Drug Pipeline Analysis
|出版日期||內容資訊||英文 265 Pages
|歐洲的老年癡呆症治療藥的開發平台分析 Europe Alzheimer Drug Pipeline Analysis|
|出版日期: 2014年01月14日||內容資訊: 英文 265 Pages||
The incidence of Alzheimer's disease has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been observed that close to 50% of dependency of aged people in Europe is attributed for by Alzheimer's disease. The rapid growth in the prevalence of Alzheimer's disease over the next few decades in Europe is expected to result in immense pressure on the social and health-care systems of the region. There is an urgent need for developing curative or disease-modifying therapies to offset the upcoming Alzheimer's disease epidemic.
"Europe Alzheimer's Drug Pipeline Analysis" by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Alzheimer disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Alzheimer drug market based upon development process.
Following parameters for each drug profile in development phase are covered in "Europe Alzheimer's Drug Pipeline Analysis" research report:
Europe Alzheimer's Disease Drug Pipeline by Clinical Phase:
Each Drug Profile has Tables Representing Following Information: